Search - tctmd.com

Displaying 181 - 200 of 3922

Sort: Relevancy | Date

News Conference News HRS 2025

GLP-1 Drugs May Have Role in Secondary Prevention of AF

Todd Neale

April 28, 2025

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Michael O'Riordan

April 25, 2025

News Daily News

Funding for Women’s Health Initiative Imperiled, but Appears Secure for Now

Yael L. Maxwell

April 25, 2025

News Daily News

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Caitlin E. Cox

April 23, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Opinion CV Team Dispatch

April 2025 Dispatch for the CV Team

L.A. McKeown

April 18, 2025

News Daily News

Black Adults Face CV Mortality Beyond Their Predicted Risk

Caitlin E. Cox

April 18, 2025

News Daily News

AHA Statement Zeroes In On Sleep Health

L.A. McKeown

April 17, 2025

News Daily News

Oral GLP-1 Drug Shines in Phase III ACHIEVE-1 Trial, Lilly Says

Caitlin E. Cox

April 17, 2025

News Daily News

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Yael L. Maxwell

April 16, 2025

News Daily News

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM

L.A. McKeown

April 15, 2025

News Daily News

Cardiotoxicity Rare With Common GI Chemotherapy

L.A. McKeown

April 15, 2025

News Daily News

High BMI Before Pregnancy Tied to Greater CVD Risk Later in Life

L.A. McKeown

April 14, 2025

News Daily News

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Caitlin E. Cox

April 14, 2025

News Daily News

Weekend Warriors Also See Mortality Benefits With Exercise

Michael O'Riordan

April 10, 2025

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

News Daily News

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

Michael O'Riordan

April 09, 2025

News Daily News

AHA Tackles Need for Increased CV Prevention in Emerging Adults

Yael L. Maxwell

April 09, 2025

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

L.A. McKeown

April 03, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

Advertisement

GLP-1 Drugs May Have Role in Secondary Prevention of AF

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Funding for Women’s Health Initiative Imperiled, but Appears Secure for Now

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

April 2025 Dispatch for the CV Team

Black Adults Face CV Mortality Beyond Their Predicted Risk

AHA Statement Zeroes In On Sleep Health

Oral GLP-1 Drug Shines in Phase III ACHIEVE-1 Trial, Lilly Says

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM

Cardiotoxicity Rare With Common GI Chemotherapy

High BMI Before Pregnancy Tied to Greater CVD Risk Later in Life

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Weekend Warriors Also See Mortality Benefits With Exercise

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

AHA Tackles Need for Increased CV Prevention in Emerging Adults

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content